Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 12/20 | 0.53 |
| ▸ | HTT | P42858 | 4/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.37 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.37 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.37 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.37 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3680873 | 0.99 | IDO1 (0.52) | IDO1HTTCYP1A2PRMT1LMNA | |
| SCHEMBL3681107 | 0.91 | IDO1 (0.47) | IDO1HTTCYP1A2PRMT1LMNA | |
| Bromide SCHEMBL4437970 | 0.88 | IDO1 (0.67) | IDO1HTTCYP1A2PRMT1LMNA | |
| Bromide SCHEMBL4440425 | 0.87 | IDO1 (0.41) | IDO1HTTCYP1A2PRMT1LMNA | |
| SCHEMBL3752992 | 0.87 | IDO1 (0.66) | IDO1HTTCYP1A2PRMT1LMNA | |
| SCHEMBL3680875 | 0.85 | IDO1 (0.40) | IDO1HTTCYP1A2PRMT1LMNA | |
| Bromide SCHEMBL4434923 | 0.82 | IDO1 (0.58) | IDO1HTTCYP1A2PRMT1LMNA | |
| Bromide SCHEMBL4915787 | 0.81 | IDO1 (0.57) | IDO1HTTCYP1A2PRMT1LMNA | |
| SCHEMBL3685292 | 0.80 | IDO1 (0.57) | IDO1HTTCYP1A2PRMT1LMNA | |
| SCHEMBL4917614 | 0.79 | IDO1 (0.56) | IDO1HTTCYP1A2PRMT1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061754-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008115999-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | FECH, SLC10A1, SLC40A1 | SLC6A2 247/4885SLC6A4 724/4885SLC6A3 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.